BioNTech wants to manufacture 25% more doses than expected this year against Covid-19

Illustration of the Pfizer vaccine developed against Covid-19. – Jaap Arriens

The German laboratory BioNTech announced on Tuesday that it intended to manufacture in 2021 up to 2.5 billion doses of its anti-coronavirus vaccine developed with the American Pfizer, or 25% more than initially announced.

Production capacities are expected to increase due to “optimization of production processes”, “expansion of the production network”, as well as the authorization to draw six doses from a vial, the company explains in a statement. She delivered with her partner, on March 23, “more than 200 million doses” in the world.



Source link